The National Institutes of Health (NIH) defines a Clinical Trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions. Clinical trials help develop novel drugs (Investigational Products) by providing early access to patients who volunteer to participate in the research study.

Carolina BioOncology Institute and our expert Providers participate in the national clinical trials listed below. The eligibility criteria enables patients with advanced solid tumors to access these Investigational Products. Over the past 15 years, our Clinic has opened over 100 Oncology clinical trials and our experienced staff are happy to discuss options for determining trial eligibility Please view the list of trials below that are currently enrolling patients:

Abbvie M20-124

A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination with aPD-1 in Subjects with Locally Advanced or Metastatic Tumors

Click here for the ClinicalTrials.gov link

AbbVie M20-431

A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors

Click here for the ClinicalTrials.gov link

Abbvie M21-404

A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors

Click here for the ClinicalTrials.gov link

AbbVie M21-410

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab

Click here for the ClinicalTrials.gov link

Adagene ADG116-P001

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG116 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors

Click here for the ClinicalTrials.gov link

Apros APR003-001

A Phase 1 dose escalation study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions

Click here for the ClinicalTrials.gov link

Ascendis ASCEN0029

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab or Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies

Click here for the ClinicalTrials.gov link

Astra Zeneca D9950C00001

A Phase 1 First-in-human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination with Durvalumab (MEDI4736) in Participants with Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

Atreca ATRC-101-A01

A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies

Click here for the ClinicalTrials.gov link

BJ Bioscience INC BJ-005-01-001US

A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients with Advanced Solid Tumor or Lymphoma

Click here for the ClinicalTrials.gov link

Bristol – Myers Squibb CA111001

Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors.

Click here for the ClinicalTrials.gov link

Conjupro CPO-100-US-101

A Phase 1, Multi-Center, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients with Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

Cullinan CLN-619-001

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

Fate Therapeutics FT536-101

A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination with Monoclonal Antibodies in Subjects with Advanced Solid Tumors

I-Mab TJ033721STM101

Phase 1 study of TJ033721 in subjects with advanced or metastatic solid tumors.

Click here for the ClinicalTrials.gov link

Immune-Onc IO-108-CL-001

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of IO-108 as Monotherapy and in Combination With Pembrolizumab, in Adult Subjects With Advanced Relapsed or Refractory Solid Tumors

Click here for the ClinicalTrials.gov link

Immune-Onc IO-202-CL-002

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors

Click here for the ClinicalTrials.gov link

InCyte INCA 0186-101

A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

InCyte INCAGN 2385-201

A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) in participants with Select Advanced Malignancies

Click here for the ClinicalTrials.gov link

InCyte INCB 123667-101

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

Jounce JTX 8064-101

Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX 8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Click here for the ClinicalTrials.gov link

Macrogenics CP-MGC018-02

A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination with MGD019 in Participants with Advanced Solid Tumors.

MedImmune D6770C00001

A Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab ± Oleclumab in Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

Molecular Templates MT-6402-001

A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1.

Click here for the ClinicalTrials.gov link

Next Cure NC762-01

A Phase 1/Phase 2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors

Click here for the ClinicalTrials.gov link

Nuvation NUV-422-02

Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Click here for the ClinicalTrials.gov link

Nuvation NUV-868-01

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

PEEL Therapeutics PEEL-224-001

An Early Phase Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

Repertoire PRIME- 102

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients with Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma

Click here for the ClinicalTrials.gov link

Repertoire TT – 101

A Phase 1/2 Study of Deep IL-15 Loaded T-Cells Alone and in Combination with Pembrolizumab in Patients with Select Solid Tumors and Lymphomas

Click here for the ClinicalTrials.gov link

Trethera TRE515-T-02

A Phase 1, Open-Label, First-In-Human, Dose-Escalation Study with Expansion to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered TRE-515 in Subjects with Solid Tumors

Click here for the ClinicalTrials.gov link

Xilio XTX101-01/02-001

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 in Patients with Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

Xilio XTX202-01/02-001

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 in Patients with Advanced Solid Tumors

Click here for the ClinicalTrials.gov link

Zenshine ZX-4081-101

A Phase 1, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients with Advanced Solid Tumors

Click here for the ClinicalTrials.gov link